The outlook of companies tied to Sildenafil's past presents a challenging investment landscape. While the initial success generated substantial gains, generic competition have significantly impacted market share . Investing in associated pharmaceutical firms now requires a discerning assessment of patent rights , evolving patient shifts , and the p